首页> 外文期刊>Analytical and quantitative cytology and histology >Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation
【24h】

Identification of annexin A13 as a regulator of chemotherapy resistance using random homozygous gene perturbation

机译:使用随机纯合基因扰动鉴定膜联蛋白A13作为化疗耐药的调节剂

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To utilize a powerful new technology for target discovery, Random Homozygous Gene Perturbation (RHGP), and to identify novel targets that cause tumor cells to become chemoresistant. STUDY DESIGN: RHGP was used to identify and validate genetic changes that cause chemoresistance of tumor cells to Rapamycin. RESULTS: A series of targets was identified that allowed tumor cells to survive treatment with Rapamycin. We validated these targets and focused on Annexin A13, a target where decreased expression caused tumor cell insensitivity to Rapamycin. Ectopic overexpression of Annexin A13 was likewise sufficient to sensitize malignant breast cancer cells to treatment with Rapamycin. CONCLUSION: These findings expand our knowledge of mechanisms that allow tumor cell drug resistance and demonstrate the power of RHGP to identify novel targets and mechanisms.
机译:目的:利用功能强大的新技术进行靶标发现,即随机纯合基因扰动(RHGP),并鉴定导致肿瘤细胞产生化学耐药性的新靶标。研究设计:RHGP用于鉴定和验证引起肿瘤细胞对雷帕霉素耐药的遗传变化。结果:确定了一系列靶标,可使肿瘤细胞在雷帕霉素治疗下存活。我们验证了这些目标,并集中于膜联蛋白A13,该目标的表达降低导致肿瘤细胞对雷帕霉素不敏感。膜联蛋白A13的异位过表达同样足以使恶性乳腺癌细胞对雷帕霉素治疗敏感。结论:这些发现扩展了我们对允许肿瘤细胞耐药的机制的认识,并证明了RHGP能够识别新的靶标和机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号